Bristol-Myers Squibb elects Thomas J. Lynch as EVP & CSO.
M2 PHARMA-March 9, 2017-Bristol-Myers Squibb elects Thomas J. Lynch as EVP & CSO
(C)2017 M2 COMMUNICATIONS
Biopharmaceutical company Bristol-Myers Squibb Company (NYSE:BMY) reported on Wednesday the addition of Thomas J. Lynch, Jr., as its executive vice president and chief scientific officer.
Effective 16 March 2017, Dr Lynch succeeds Dr Francis Cuss, who will retire from the company, but will serve as an advisor for the next three months to ensure a seamless transition. In conjunction, Dr Lynch will resign from the company's board of directors on 15 March 2017.
Most recently, Dr Lynch has served as chair and chief executive officer of Massachusetts General Physicians Organisation and as a member of its board from 2015 to 2017.
Previously, Dr Lynch was the director of Yale Cancer Center, the Richard and Jonathan Sackler Professor of Internal Medicine at the Yale School of Medicine, the physician in chief of Smilow Cancer Hospital, Yale-New Haven, professor of Medicine at Harvard Medical School as well as chief of Hematology/Oncology at Massachusetts General Hospital.
Currently, Dr Lynch is a member of the American Association for Cancer Research, the American Society of Clinical Oncology and the International Association for the Study of Lung Cancer.
((Comments on this story may be sent to firstname.lastname@example.org))
|Printer friendly Cite/link Email Feedback|
|Date:||Mar 9, 2017|
|Previous Article:||Perrigo reports final approval and OTC launch of new store foam brand equivalent to Women's Rogaine 5% minoxidil foam.|
|Next Article:||Innovus Pharma to commercialise Sensum+ in the EU following the CPNP notification.|